ArticlePLoS medicine2022
The association between multimorbidity and mobility disability-free life expectancy in adults aged 85 years and over: A modelling study in the Newcastle 85+ cohort.
Article in PLoS medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- The prevalence of disability in older adults with multimorbidity: a meta-analysis.Aging clinical and experimental research · 2024Pooled it
- Social and Health Conditions That Drive the Need and Demand for, Use of and Expenditure on Social Care in the UK: A Systematic Review.Cochrane evidence synthesis and methods · 2026Review
- Safety and short-term outcomes of robotic surgery for colorectal cancer in the very elderly (≥ 85 Years): a multicenter propensity score-matched study.Surgery today · 2026Article
- Frailty and major late-life transitions in very old adults: contrasting biomarker patterns of GDF-15 and NT-proBNP in the Kawasaki Aging and Wellbeing Project.GeroScience · 2026Article
- Disability free life expectancy: a simulation study of scenarios to extend healthy years and reduce inequalities.BMC medicine · 2026Article
- Are participants with disability referred for social prescribing? Findings from the English Longitudinal Study of Ageing.Journal of public health (Oxford, England) · 2026Article
- Association Between Function-focused Training and Physical Function Among Community-dwelling Oldest-old Individuals: A Retrospective Study.Juntendo medical journal · 2026Article
- Biological Age Acceleration Associated with the Progression Trajectory of Cardio-Renal-Metabolic Multimorbidity: A Prospective Cohort Study.Nutrients · 2025Article
- Critical Illness, Major Surgery, and Other Hospitalizations and Active and Disabled Life Expectancy.JAMA network open · 2025Article
- Contribution of depression and cardiometabolic diseases and the role of depression treatment in survival and functioning in older adults.EClinicalMedicine · 2025Article
- From curing to caring: exploring social care needs after the onset of chronic conditions among European older adults (50+).Innovation in aging · 2025Article
- Article
- Magnitude of multimorbidity and associated factors among stroke survivors in public hospitals of Ethiopia.Journal of multimorbidity and comorbidityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMobility disability is predictive of further functional decline and can itself compromise older people's capacity (and preference) to live independently. The world's population is also ageing, and multimorbidity is the norm in those aged ≥85. What is unclear in this age group, is the influence of multimorbidity on (a) transitions in mobility disability and (b) mobility disability-free life expectancy (mobDFLE). METHODS AND
findingsUsing multistate modelling in an inception cohort of 714 85-year-olds followed over a 10-year period (aged 85 in 2006 to 95 in 2016), we investigated the association between increasing numbers of long-term conditions and (1) mobility disability incidence, (2) recovery from mobility disability and (3) death, and then explored how this shaped the remaining life expectancy free from mobility disability at age 85. Models were adjusted for age, sex, disease group count, BMI and education. We defined mobility disability based on participants' self-reported ability to get around the house, go up and down stairs/steps, and walk at least 400 yards; participants were defined as having mobility disability if, for one or more these activities, they had any difficulty with them or could not perform them. Data were drawn from the Newcastle 85+ Study: a longitudinal population-based cohort study that recruited community-dwelling and institutionalised individuals from Newcastle upon Tyne and North Tyneside general practices. We observed that each additional disease was associated with a 16% increased risk of incident mobility disability (hazard ratio (HR) 1.16, 95% confidence interval (CI): 1.07 to 1.25, p < 0.001), a 26% decrease in the chance of recovery from this state (HR 0.74, 95% CI: 0.63 to 0.86, p < 0.001), and a 12% increased risk of death with mobility disability (HR: 1.12, 95% CI: 1.07- to .17, p < 0.001). This translated to reductions in mobDFLE with increasing numbers of long-term conditions. However, residual and unmeasured confounding cannot be excluded from these analyses, and there may have been unobserved transitions to/from mobility disability between interviews and prior to death.
conclusionsWe suggest 2 implications from this work. (1) Our findings support calls for a greater focus on the prevention of multimorbidity as populations age. (2) As more time spent with mobility disability could potentially lead to greater care needs, maintaining independence with increasing age should also be a key focus for health/social care and reablement services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.